KR900005044B1 - 종양치료제의 오일상 조성물의 제조방법 - Google Patents

종양치료제의 오일상 조성물의 제조방법 Download PDF

Info

Publication number
KR900005044B1
KR900005044B1 KR1019830000188A KR830000188A KR900005044B1 KR 900005044 B1 KR900005044 B1 KR 900005044B1 KR 1019830000188 A KR1019830000188 A KR 1019830000188A KR 830000188 A KR830000188 A KR 830000188A KR 900005044 B1 KR900005044 B1 KR 900005044B1
Authority
KR
South Korea
Prior art keywords
oil
tumor
residue
mixture
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR1019830000188A
Other languages
English (en)
Korean (ko)
Other versions
KR840003028A (ko
Inventor
히로이쯔 가와따
다다요시 오무라
슌지 하스미
유따까 곤노
마사요시 아루가
세이끼 다시로
도시미쯔 곤노
겐 이와이
Original Assignee
야마노우찌 세이야꾸 가부시끼 가이샤
모리오까 시게오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP799782A external-priority patent/JPS58124714A/ja
Application filed by 야마노우찌 세이야꾸 가부시끼 가이샤, 모리오까 시게오 filed Critical 야마노우찌 세이야꾸 가부시끼 가이샤
Publication of KR840003028A publication Critical patent/KR840003028A/ko
Application granted granted Critical
Publication of KR900005044B1 publication Critical patent/KR900005044B1/ko
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019830000188A 1982-01-20 1983-01-19 종양치료제의 오일상 조성물의 제조방법 Expired KR900005044B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP799782A JPS58124714A (ja) 1982-01-20 1982-01-20 抗腫瘍物質の油性組成物
JP7997 1982-01-20
JP57-7997 1982-01-20
JP21504982 1982-12-08
JP215049 1982-12-08

Publications (2)

Publication Number Publication Date
KR840003028A KR840003028A (ko) 1984-08-13
KR900005044B1 true KR900005044B1 (ko) 1990-07-18

Family

ID=26342413

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019830000188A Expired KR900005044B1 (ko) 1982-01-20 1983-01-19 종양치료제의 오일상 조성물의 제조방법

Country Status (6)

Country Link
US (1) US4578391A (enExample)
KR (1) KR900005044B1 (enExample)
DE (1) DE3301638A1 (enExample)
FR (1) FR2519864B1 (enExample)
GB (1) GB2114885B (enExample)
IT (1) IT1193128B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6028916A (ja) * 1983-07-13 1985-02-14 Yamanouchi Pharmaceut Co Ltd アクラルビシンまたはその塩酸塩の油性組成物
AT388499B (de) * 1985-08-02 1989-06-26 Merz & Co Gmbh & Co Verfahren zur herstellung einer antiviralen und antitumor-zusammensetzung, und deren verwendung
US5389366A (en) * 1986-09-19 1995-02-14 Yamanouchi Pharmaceutical Co., Ltd. Neocarzinostatin derivative composition for oral administration
JP2556865B2 (ja) * 1986-09-19 1996-11-27 山之内製薬株式会社 ネオカルチノスタチン誘導体の非注射投与用組成物
US5051406A (en) * 1987-03-04 1991-09-24 Nippon Hypox Laboratories Incorporated Pharmaceutical composition using albumin as a carrier and process for producing the same
JPH0794377B2 (ja) * 1987-07-22 1995-10-11 呉羽化学工業株式会社 エストラジオール誘導体を含有する注射剤
US5216011A (en) * 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
US5496533A (en) * 1992-07-31 1996-03-05 Australian Nuclear Science & Technology Organisation Rhenium complexes
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
GB9323588D0 (en) * 1993-11-16 1994-01-05 Cortecs Ltd Hydrophobic preparation
GB9422990D0 (en) * 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
GB9424901D0 (en) * 1994-12-09 1995-02-08 Cortecs Ltd Sequestration Agents
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
GB9618420D0 (en) * 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6117852A (en) * 1997-12-29 2000-09-12 National Science Council Boron-containing lipiodol for boron neutron capture therapy of hepatoma
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
AU755443C (en) * 1998-07-20 2006-08-17 Virbac (Australia) Pty Limited Bioimplant formulation
CN1243543C (zh) 1998-07-20 2006-03-01 派普泰克有限公司 生物植入物配方
US8052982B2 (en) * 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
US6463256B2 (en) * 1999-03-31 2002-10-08 Hewlett-Packard Company Duplexing module for printer
US6831079B1 (en) 1999-09-27 2004-12-14 American Cyanamid Company Vasopressin agonist formulation and process
US6420358B1 (en) 1999-09-27 2002-07-16 American Cyanamid Company Vasopressin antagonist and diuretic combination
US6352718B1 (en) 1999-09-27 2002-03-05 American Cyanamid Company Vasopressin antagonist formulation and process
US6437006B1 (en) 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
DE60111352T2 (de) * 2000-01-20 2006-05-04 Supratek Pharma, Inc., Montreal Podophyllotoxin-zusammensetzungen
AUPR644301A0 (en) * 2001-07-17 2001-08-09 Unisearch Limited Method and composition for treatment of cancer
US7094771B2 (en) * 2002-07-15 2006-08-22 National Tsing Hua University Pharmaceutical composition for boron neutron capture therapy containing triphenylboroxin
JP2006056781A (ja) * 2002-11-15 2006-03-02 Bioserentack Co Ltd 界面活性剤を含む固形化製剤
US7423004B2 (en) * 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
CN102260216A (zh) * 2010-05-28 2011-11-30 李茂全 5-氟尿嘧啶亲脂性衍生物碘化油
CN111298189A (zh) * 2018-12-11 2020-06-19 陈传果 一种易于推注的碘化油栓塞剂及其制备方法
CN109821055A (zh) * 2019-02-01 2019-05-31 厦门大学 一种药物-碘油溶剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5393M (enExample) * 1964-09-22 1967-10-30
US4104461A (en) * 1973-04-16 1978-08-01 Research Corporation 2,2'-Anhydro-β-D-arabinofuranosyl-5-fluorocytosine
US4011661A (en) * 1973-10-30 1977-03-15 Kyowa Hakko Kogyo Co., Ltd. Powdered emulsion product and method of production
JPS5439098A (en) * 1977-08-31 1979-03-24 Kyowa Hakko Kogyo Co Ltd Mitomycin c derivatives
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
GB2046092B (en) * 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
JPS5686114A (en) * 1979-12-17 1981-07-13 Medeiseru Kenkyusho:Kk Pharmaceutical composition for suppository

Also Published As

Publication number Publication date
DE3301638C2 (enExample) 1989-08-24
IT1193128B (it) 1988-06-02
DE3301638A1 (de) 1983-08-04
US4578391A (en) 1986-03-25
KR840003028A (ko) 1984-08-13
IT8367055A0 (it) 1983-01-19
GB2114885B (en) 1985-09-04
FR2519864A1 (fr) 1983-07-22
GB8301566D0 (en) 1983-02-23
GB2114885A (en) 1983-09-01
FR2519864B1 (fr) 1985-09-27

Similar Documents

Publication Publication Date Title
KR900005044B1 (ko) 종양치료제의 오일상 조성물의 제조방법
DE69325256T2 (de) Insizierbare lecithin gel
DE69433723T2 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
DE68905374T2 (de) Mittel zur vorbeugung und abhilfe gegen ischaemische verletzungen.
CA1203173A (en) Fat emulsion containing prostaglandin e.sub.1 and method for production thereof
DE3686221T2 (de) Emulsionen zur parenteralen und/oder oralen verabreichung schwer wasserloeslicher ionisierbarer hydrophober arzneistoffe.
JPH07509397A (ja) エマルジョン含有の，高度にフッ素化した塩素置換有機化合物，およびそれらを合成しそして使用する方法
Unger et al. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients
JPH06157294A (ja) 脂肪微粒子製剤
DE3883206T2 (de) Arzneistoff enthaltende fettemulsion des typs "kurz vor gebrauch hergestellt" sowie verfahren zur herstellung einer arzneihaltigen fettemulsion.
FI98047C (fi) Röntgenvarjoaineena käytettävä jodipitoinen emulsio
JPS59122423A (ja) 制癌剤含有脂肪乳剤
JPH0420887B2 (enExample)
US3170836A (en) Injectable compositions comprising a copper-containing chelate complex compound dispersed in a stabilized oil-in-water emulsion and method of using the same
KR910002638B1 (ko) 아클라루비신 또는 이의 염산염의 유성 조성물의 제조방법
JPWO2004047846A1 (ja) グリチルリチン含有界面活性剤相中油型ゲル組成物
JPS62192327A (ja) 抗腫瘍物質徐放性製剤
Carr et al. Lymphatic metastasis; lymphangiochemotherapy of mammary cancer: ascitic form of rat mammary adenocarcinoma 13762
JPS60166626A (ja) 血管造影剤
CN107073129B (zh) 亲水性药物的靶向递送
JPH0524132B2 (enExample)
JPH0314522A (ja) 化学・免疫学的抗癌物質製剤
JPS63303925A (ja) 制癌剤組成物
Kar et al. The pharmacology of hepatic regional administration of cisplatin in a rabbit model
McClendon et al. Absorption rates of colloid and milky suspensions of halogenated fats for hepatosplenography in the rat

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 19950710

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19960719

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19960719

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301